Mycobacterium tuberculosis modulates phosphorylation of host ATP6V1E1 to promote intracellular survival

J Jianxia Chen F Fen Tang L Lianhua Qin W Weijun Fang L Liru Guan X Xiangyang Wu H Haohao Li Y Yongjia Duan F Fei Wang C Cheng Peng (College of Chemistry and Molecular Engineering) Z Zhonghua Liu J Jie Wang (State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences Beijing China) X Xiaochen Huang L Lin Wang H Hua Yang (State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China) L Li Wang (The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou China) W Wei Sha X Xia Cai L Liang-Dong Lyu H Haipeng Liu F Feng Liu B Baoxue Ge R Ruijuan Zheng

Abstract

Abstract Intracellular pathogens such as Mycobacterium tuberculosis (Mtb) can promote their survival within infected cells by preventing lysosomal acidification. Here, we report that Mtb secretes a protein (Rv1184, or acyltransferase Chp2) that inhibits lysosomal acidification by targeting the host vacuolar ATPase (V-ATPase). We show that phosphorylation of the V-ATPase E1 subunit (ATP6V1E1) at Tyr56/57 suppresses lysosomal acidification through inhibition of V-ATPase assembly. Further investigation reveals that tyrosine kinase BMX promotes phosphorylation of ATP6V1E1. Strikingly, Chp2 increases BMX-dependent phosphorylation of ATP6V1E1, apparently by directly binding ATP6V1E1 and facilitating its interaction with BMX. Furthermore, inhibition of BMX impairs Mtb growth within macrophages and in mice. Thus, our work reveals a mechanism for the regulation of lysosomal acidification and suggests lysosomal acidification modulation as a potential approach for host-directed therapy against Mtb.

Article Details

Volume / Issue Vol. 17, Issue 1
Published February 06, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (23)

J

Jianxia Chen

F

Fen Tang

L

Lianhua Qin

W

Weijun Fang

L

Liru Guan

X

Xiangyang Wu

H

Haohao Li

Y

Yongjia Duan

F

Fei Wang

C

Cheng Peng

College of Chemistry and Molecular Engineering

Z

Zhonghua Liu

J

Jie Wang

State Key Laboratory of Molecular Oncology, Beijing Key Laboratory, CAMS Key Laboratory of Translational Research on Lung Cancer, Department of Medical Oncology Cancer Hospital, Chinese Academy of Medical Sciences Beijing China

X

Xiaochen Huang

L

Lin Wang

H

Hua Yang

State Key Laboratory of Natural Medicines, School of Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China

L

Li Wang

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou China

W

Wei Sha

X

Xia Cai

L

Liang-Dong Lyu

H

Haipeng Liu

F

Feng Liu

B

Baoxue Ge

R

Ruijuan Zheng